REG - ValiRx PLC - Inaphaea Co-Marketing Agreement

ValiRxAnnouncement

24/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240924:nRSX3310Fa&default-theme=true

RNS Number : 3310F  ValiRx PLC  24 September 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Inaphaea Co-Marketing Agreement

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

ValiRx is pleased to confirm the execution of a Memorandum of Understanding
(the "Agreement") with emerging UK drug turnaround biotech Ignota Labs Limited
("Ignota Labs"), to collaborate on the exchange of data from Inaphaea's
Biobank to generate insights, co-develop new assets, and explore joint
business opportunities, including grant funding.

Ignota Labs will be entitled to analyse Inaphaea's Biobank data to develop or
improve in-silico models which will support sourcing of new onocology assets
with the intention of co-developing these assets using Inaphaea's tCRO®
services and Ignota Labs' in-silico platform. The in-silico models will also
be used for future services offered by Ignota Labs. Any revenues generated
from the co-developed assets or servies will be shared between Ignota Labs and
ValiRx, subject to a further revenue-sharing agreement to be agreed upon.

 

Mark Eccleston, CEO of ValiRx commented "ValiRx has utilised Ignota Labs'
in-silico tox screening services for its in house evaluation projects and was
impressed with the performance. This agreement leverages the data sets from
Inaphaea's biobank to further develop Ignota Labs' in-silico capabilities
which will benefit our early stage evaluation as well as providing an exciting
new AI approach to asset discovery."

Sam Windsor CEO of Ignota Labs, commented "Ignota Labs has successfully
developed a proprietary AI model, SAFEPATH, which applies a deep learning
approach combined bioinformatics and cheminformatics datasets to solve drug
safety issues. Inaphaea's data sets will be used to develop the next iteration
of SAFEPATH and improve identification of the mechanisms of drug toxicity,
predict effects on the human body, and balance that with therapeutic
effectiveness. We can apply this approach to clinical candidates that have
failed do to toxicity issues, stratify those which can be addressed and
potentially identify new candidates, all based on in-silico modelling."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS ***

 

 

 

 

 

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 115 784 0026

                                                   www.valirx.com

 Dr Mark Eccleston, CEO                            info@valirx.com (about%3Ablank)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (https://www.vformation.biz/)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (https://www.valirx.com/)

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUOARRSKUKUUR